Citations

Clear

5 citation(s) found for "Steenwijk, MD".

White matter hyperintensities associate with pathological stages of neurodegenerative disease.
Lin, Chen‐Pei , Bouwman, Maud M.A. , Reijner, Niels , Steenwijk, Martijn D. , Jonkman, Laura E. , Frigerio, Irene , Noteboom, Samantha , Preziosa, Paolo , Boon, Baayla D.C. , Bouwman, Femke H. , Rozemüller, Annemieke J.M. , Barkhof, Frederik , Berg, Wilma D. J. van de

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.079560 Get It

AbstractBackgroundWhite matter hyper‐intensities (WMH) are observed on FLAIR MRI, increase with age and are more prominent in neurodegenerative diseases such as in Alzheimer’s disease (AD) and Parkinson’s disease (PD). The aim of this study was to assess the association between WMH and neuropathological staging of amyloid‐beta, neurofibrillary tangles (NFT) and α‐synuclein (α‐syn).MethodIn‐situ 3T‐MRI 3DT1‐weighted and 3D‐FLAIR data were collected for 77 clinically defined and pathologically‐confirmed brain donors; 31 AD, 21 PD and PD dementia (PDD), and 25 controls. WMH were segmented on FLAIR using an in‐house developed multiview convolutional neural network, followed by manual checking, and volume was obtained with FSL. Fifteen brain regions were dissected at autopsy, immunostained and evaluated for neuropathological diagnosis, including Thal amyloid phase, CAA type, and Braak stages for NFT and α‐syn. Group differences were assessed with linear models (corrected for age, gender, post‐mortem delay), and associations with Spearman and Pearson partial correlations.ResultCompared to controls, WMH load was higher in AD (p<0.001), specifically amnestic AD (p = 0.003) rather than non‐amnestic AD (p = 0.053), and higher in PD (p = 0.016), specifically non‐demented PD (p = 0.015) rather than PDD (p = 1.0). No difference in gender was observed (p = 0.38). Without the influence of pathology (in controls), WMH was associated with age (r = 0.49,p = 0.016).In the whole cohort, WMH was associated with Fazekas score (r = 0.67; p<0.001), normalized brain volume (NBV; r = ‐0.31,p = 0.007), gray matter volume (NGMV; r = ‐0.36,p = 0.002), Thal phase (r = 0.24,p0.034), Braak NFT stage (r = 0.33,p = 0.004), and Braak α‐syn stage (r = 0.27, p0.018).Across controls and AD, WMH associated with NBV (r = ‐0.39,p = 0.004), NGMV (r = ‐0.42,p = 0.002), left and right hippocampal volume (r = ‐0.36,p = 0.008 and r = ‐0.32,p = 0.022), Braak NFT (r = 0.41,p<0.001), Thal phase (r = 0.41,p = 0.002), and CAA (r = 0.34,p = 0.01). Amnestic and non‐amnestic AD showed similar results, except for CAA, which was associated with WMH in non‐amnestic AD only (r = 0.33,p = 0.04).Across controls and PD(D), WMH associated with Braak NFT stage (r = 0.39,p = 0.008) and Braak α‐syn stage (r = 0.60,p<0.001), but not with MRI outcome measures. In this respect PD and PDD showed different results; in PD WMH associated with NGMV (r = ‐0.37,p = 0.031), in PDD with left and right hippocampal volume (r = ‐0.44,p = 0.014 and r = ‐0.44,p = 0.015).ConclusionWMH associate with pathological stages of AD and PD(D), and contributes to MRI atrophy.
White matter hyperintensities associate with pathological stages of neurodegenerative disease
Lin, Chen‐Pei , Bouwman, Maud M.A. , Reijner, Niels , Steenwijk, Martijn D. , Jonkman, Laura E. , Frigerio, Irene , Noteboom, Samantha , Preziosa, Paolo , Boon, Baayla D.C. , Bouwman, Femke H. , Rozemüller, Annemieke J.M. , Barkhof, Frederik , Berg, Wilma D. J. van de

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S10 | Pages: No page available

10.1002/alz.081915 Get It

AbstractBackgroundWhite matter hyper‐intensities (WMH) are observed on FLAIR MRI, increase with age and are more prominent in neurodegenerative diseases such as in Alzheimer’s disease (AD) and Parkinson’s disease (PD). The aim of this study was to assess the association between WMH and neuropathological staging of amyloid‐beta, neurofibrillary tangles (NFT) and a‐synuclein (a‐syn).MethodIn‐situ 3T‐MRI 3DT1‐weighted and 3D‐FLAIR data were collected for 77 clinically defined and pathologically‐confirmed brain donors; 31 AD, 21 PD and PD dementia (PDD), and 25 controls. WMH were segmented on FLAIR using an in‐house developed multiview convolutional neural network, followed by manual checking, and volume was obtained with FSL. Fifteen brain regions were dissected at autopsy, immunostained and evaluated for neuropathological diagnosis, including Thal amyloid phase, CAA type, and Braak stages for NFT and a‐syn. Group differences were assessed with linear models (corrected for age, gender, post‐mortem delay), and associations with Spearman and Pearson partial correlations.ResultCompared to controls, WMH load was higher in AD (p<0.001), specifically amnestic AD (p = 0.003) rather than non‐amnestic AD (p = 0.053), and higher in PD (p = 0.016), specifically non‐demented PD (p = 0.015) rather than PDD (p = 1.0). No difference in gender was observed (p = 0.38). Without the influence of pathology (in controls), WMH was associated with age (r = 0.49,p = 0.016). In the whole cohort, WMH was associated with Fazekas score (r = 0.67; p<0.001), normalized brain volume (NBV; r = ‐0.31,p = 0.007), gray matter volume (NGMV; r = ‐0.36,p = 0.002), Thal phase (r = 0.24,p0.034), Braak NFT stage (r = 0.33,p = 0.004), and Braak a‐syn stage (r = 0.27, p0.018). Across controls and AD, WMH associated with NBV (r = ‐0.39,p = 0.004), NGMV (r = ‐0.42,p = 0.002), left and right hippocampal volume (r = ‐0.36,p = 0.008 and r = ‐0.32,p = 0.022), Braak NFT (r = 0.41,p<0.001), Thal phase (r = 0.41,p = 0.002), and CAA (r = 0.34,p = 0.01). Amnestic and non‐amnestic AD showed similar results, except for CAA, which was associated with WMH in non‐amnestic AD only (r = 0.33,p = 0.04). Across controls and PD(D), WMH associated with Braak NFT stage (r = 0.39,p = 0.008) and Braak a‐syn stage (r = 0.60,p<0.001), but not with MRI outcome measures. In this respect PD and PDD showed different results; in PD WMH associated with NGMV (r = ‐0.37,p = 0.031), in PDD with left and right hippocampal volume (r = ‐0.44,p = 0.014 and r = ‐0.44,p = 0.015).ConclusionWMH associate with pathological stages of AD and PD(D), and contributes to MRI atrophy.
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
Acosta‐Medina, Aldo A. , Kemps, Paul G. , Zondag, Timo C. E. , Abeykoon, Jithma P. , Forma-Borst, Jelske, Steenwijk, Eline C., Feijen, Elizabeth A. M. , Teepen, Jop C. , Bennani, N. Nora , Schram, Susan, Davidge‐Pitts, Caroline , Ryu, Jay H. , Vassallo, Robert , Dasari, Surendra , Ravindran, Aishwarya , Cleven, Arjen H.G. , Balgobind, Brian V. , Saeed, Peerooz , Bramer, Jos A. M. , Groen, Ruben A. L. de , Tonino, Sanne H. , Bos, Cor van den , Laar, Jan van , Halteren, Astrid G. S. van , Schram, Susan M, Shah, Mithun V , Davidge-Pitts, Caroline , Koster, Matthew J , Ryu, Jay H , Tobin, W Oliver , Young, Jason R , Dasari, Surendra , Rech, Karen , Ravindran, Aishwarya , Cleven, Arjen H G , Verdijk, Robert M , van Noesel, Carel J M , Balgobind, Brian V , Bouma, Gerrit Joan , Saeed, Peerooz , Bramer, Jos A M , de Groen, Ruben A L , Vermaat, Joost S P , van de Sande, Michiel A J , Smit, Egbert F , Langerak, Anton W , van Wezel, Tom , Tonino, Sanne H , van den Bos, Cor , van Laar, Jan A M , Go, Ronald S , Goyal, Guarav , van Halteren, Astrid G S , Vassallo, Robert , Bennani, N Nora , Acosta-Medina, Aldo A , Shah, Meera , Koster, Matthew J. , Tobin, W. Oliver , Young, Jason R. , Rech, Karen L. , Verdijk, Robert M. , Noesel, Carel J.M. van , Sande, Michiel A. J. van de , Langerak, Anton W. , Go, Ronald S. , Goyal, Gaurav

Mayo Clinic

Blood | August 18, 2023 | Volume: 142 | Issue: 18 | Pages: 1570-1575

10.1182/blood.2023021212 | PMID 37595284 Get It

Abstract In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.
Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study
Tillema, JM, Hulst, Hanneke E. , Rocca, Maria A. , Vrenken, Hugo , Steenwijk, MD, Damjanovic, Dusan , Tedeschi, Gioacchino , Gallo, Antonio , Ciccarelli, Olga , Montalbán, Xavier , Stefano, Nicola De , Stromillo, ML, Filippi, Massimo , Barkhof, Frederik , Group, on behalf of the MAGNIMS Study, Tillema, JM, Enzinger, Christian , Ropele, Stefan , Rovira, Àlex , Group, on behalf of the MAGNIMS Study, Filippi, Massimo , Barkhof, Frederik , Rocca, Maria A , Ciccarelli, Olga

Mayo Clinic

Multiple Sclerosis Journal | October 2, 2015 | Volume: 22 | Issue: 7 | Pages: 901-909

10.1177/1352458515607650 | PMID 26432859 Get It

Objectives: The objectives of this paper are to compare in a multicenter setting patterns of regional cortical thickness in patients with relapsing–remitting multiple sclerosis (RRMS) and cognitive impairment (CI) and those cognitively preserved (CP), and explore the relationship between cortical thinning and cognitive performance. Methods: T1-weighted isotropic brain scans were collected at 3T from seven European centers in 60 RRMS patients and 65 healthy controls (HCs). Patients underwent clinical and neuropsychological examinations. Cortical thickness (CTh) measures were calculated using FreeSurfer (failing in four) and both lobar and vertex-based general linear model (GLM) analyses were compared between study groups. Results: Twenty (36%) MS patients were classified as CI. Mean global CTh was smaller in RRMS patients compared to HCs (left 2.43 vs. 2.53 mm, right 2.44 vs. 2.54 mm, p < 0.001). Multivariate GLM regional analysis showed significantly more temporal thinning in CI compared to CP patients. Verbal memory scores correlated to regional cortical thinning in the insula whereas visual memory scores correlated to parietal thinning. Conclusions: This multicenter study showed mild global cortical thinning in RRMS. The extent of thinning is less pronounced than previously reported. Only subtle regional differences between CI and CP patients were observed, some of which related to specific cognitive domains.
Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability
Daams, Marita , Weiler, Florian , Steenwijk, Martijn D. , Hahn, Horst K. , Geurts, Jeroen J.G. , Schijndel, Ronald A. van , Balk, Lisanne J. , Tewarie, Prejaas , Tillema, Jan‐Mendelt , Killestein, Joep , Uitdehaag, Bernard M.J. , Barkhof, Frederik , Vrenken, Hugo , Barkhof, Frederik

Mayo Clinic

Multiple Sclerosis Journal | May 9, 2014 | Volume: 20 | Issue: 14 | Pages: 1860-1865

10.1177/1352458514533399 | PMID 24812042 Get It

Background: The majority of patients with multiple sclerosis (MS) present with spinal cord pathology. Spinal cord atrophy is thought to be a marker of disease severity, but in long-disease duration its relation to brain pathology and clinical disability is largely unknown. Objective: Our aim was to investigate mean upper cervical cord area (MUCCA) in patients with long-standing MS and assess its relation to brain magnetic resonance imaging (MRI) measures and clinical disability. Methods: MUCCA was measured in 196 MS patients and 55 healthy controls using 3DT1-weighted cervical images obtained at 3T MRI. Clinical disability was measured using the Expanded Disability Status Scale (EDSS), Nine-Hole-Peg test (9-HPT), and 25 feet Timed Walk Test (TWT). Stepwise linear regression was performed to assess the association between MUCCA and MRI measures, and between MUCCA and clinical disability. Results: MUCCA was smaller (mean 11.7%) in MS patients compared with healthy controls (72.56±9.82 and 82.24±7.80 mm 2 respectively; p<0.001), most prominently in male patients. MUCCA was associated with normalized brain volume, and number of cervical cord lesions. MUCCA was independently associated with EDSS, TWT, and 9-HPT. Conclusion: MUCCA was reduced in MS patients compared with healthy controls. It provides a relevant marker for clinical disability in long-standing disease, independent of other MRI measures.